TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05454592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Coping Online Outreach Program
Description: 3 videos and a resource library disseminated over the course of 9 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Coping Online Outreach Program
Description: 3 videos and a resource library disseminated over the course of 9 weeks.
Study: NCT02048787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Subjects will receive a single dose of 50 mg buparlisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Subjects will receive a single dose of 50 mg buparlisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Subjects will receive a single dose of 50 mg buparlisib.
Study: NCT00928681

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single iv dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single iv dose
Study: NCT00928681

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single iv dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single dose-group A
Description: PF-00547659, single dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single dose-group A
Description: PF-00547659, single dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose-Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose- Group B
Description: PF-00547659, multiple dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multiple dose-Group B
Description: PF-00547659, multiple dose
Study: NCT02669433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg
Description: once daily, oral, 35-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 70 mg
Description: once daily, oral, 35-mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study: NCT04661657

Intervention type: OTHER
Intervention: Transthoracic echocardiogram (TTE)
Description: Subjects will undergo TTE imaging.

Intervention type: OTHER
Intervention: Transthoracic echocardiogram (TTE)
Description: Subjects will undergo TTE imaging.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance (CMR) Imaging
Description: Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance (CMR) Imaging
Description: Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
Study: NCT00870571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose
Description: A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
Study: NCT00229723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: intravenous infusion

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiation therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiation therapy
Study: NCT00870571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorvasC® 10 mg Tablets
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
Study: NCT02516683

Intervention type: OTHER
Intervention: Shigella sonnei infection
Description: A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
Study: NCT02850029

Intervention type: OTHER
Intervention: Observational study, no intervention
Study: NCT00776958

Intervention type: OTHER
Intervention: Questionnaire
Description: Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
Study: NCT02421315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment
Description: CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
Study: NCT02883153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium-89 girentuximab PET/CT
Description: Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
Study: NCT04203784

Intervention type: OTHER
Intervention: Plasma concentration measurements
Description: Plasma concentration measurements

Intervention type: OTHER
Intervention: Plasma concentration measurements
Description: Plasma concentration measurements
Study: NCT04077645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun salutations
Description: This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
Study: NCT00229723

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa)
Description: 500 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa)
Description: 500 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib (Iressa)
Description: 500 mg oral tablet
Study: NCT00751556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 660mg
Description: Extended release Naproxen Sodium (660mg) administered once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Aleve 220 mg
Description: Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
Study: NCT03521843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation only
Description: The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation+local drug delivery
Description: The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
Study: NCT02156167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP810 and Codacs™ system test
Description: Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
Study: NCT04504123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: Doxycycline Hyclate capsules, USP 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02374138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental stress management
Description: The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
Study: NCT00886405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Description: Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
Study: NCT04643561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travelan OTC
Description: 5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
Study: NCT03138655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.
Study: NCT03234959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareToy intervention
Description: Infants will perform goal directed activities inside the CareToy System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Massage
Description: Infants will received IM by their parents
Study: NCT03136822

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Dressing
Description: Standard dressing is applied for treatment of diabetic foot ulcers
Study: NCT03280303

Intervention type: OTHER
Intervention: non-interventional
Study: NCT04733261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic mobility
Description: Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy
Description: Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
Study: NCT02931929

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-NeoBOMB1, 2-vial kit
Description: intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
Study: NCT03590769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
Study: NCT03219190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LST High School Online
Description: The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
Study: NCT03865108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Description: This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound imaging
Description: This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical speculum examination
Description: This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical speculum examination
Description: This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
Study: NCT04261972

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS
Study: NCT04077645

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seated rest
Description: This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
Study: NCT00964912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.025 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.1 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.25 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.5 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 1 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 2 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 3 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 5 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 8 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose
Study: NCT04332393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
Study: NCT04379791

Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.

Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
Study: NCT02602444

Intervention type: DRUG
Intervention: ticagrelor
Description: 180 mg loading dose

Intervention type: DRUG
Intervention: ticagrelor
Description: 180 mg loading dose
Study: NCT02996292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional brackets
Description: Treating of crowding using traditional brackets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Description: Treating of crowding using active self-ligating brackets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Description: Treating of crowding using passive self-ligating brackets
Study: NCT00776087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring provided by Biotronik ICD and CRT-D devices
Description: Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Home Monitoring
Description: Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
Study: NCT01994291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Four 50mg tablets PF-04634817 once a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masked Sham Therapy
Description: Empty, needle-less syringe is used by the unmasked team once a month.
Study: NCT03886415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
Study: NCT00964912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose
Study: NCT04363827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine